As the increase in glucose after an oral glucose challenge is accompanied by an increase in insulin levels, it is unclear whether short-term hyperglycemia or hyperinsulinemia is responsible for the CILP-2 release. The gene discussed is CILP2; the disease is Hyperinsulinemia.